## Antonella Papa

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1750732/antonella-papa-publications-by-year.pdf

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

31	2,797	16	<b>32</b>
papers	citations	h-index	g-index
32	3,170 ext. citations	15.4	4.76
ext. papers		avg, IF	L-index

#	Paper	IF	Citations
31	Distinctive molecular features of regenerative stem cells in the damaged male germline <i>Nature Communications</i> , <b>2022</b> , 13, 2500	17.4	1
30	Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments. <i>Cells</i> , <b>2021</b> , 10,	7.9	13
29	INPP4B promotes PI3KEdependent late endosome formation and Wnt/Etatenin signaling in breast cancer. <i>Nature Communications</i> , <b>2021</b> , 12, 3140	17.4	6
28	Generation and functional characterization of murine mammary organoids. STAR Protocols, 2021, 2, 100	)76Б	1
27	Control of Glucocorticoid Receptor Levels by PTEN Establishes a Failsafe Mechanism for Tumor Suppression. <i>Molecular Cell</i> , <b>2020</b> , 80, 279-295.e8	17.6	6
26	PTEN and Other PtdIns(3,4,5)P Lipid Phosphatases in Breast Cancer. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	16
25	PtdIns(3,4,5)P-dependent Rac exchanger 1 (P-Rex1) promotes mammary tumor initiation and metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 28056-28067	11.5	3
24	Intragenic antagonistic roles of protein and circRNA in tumorigenesis. <i>Cell Research</i> , <b>2019</b> , 29, 628-640	24.7	70
23	Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway. <i>Science</i> , <b>2019</b> , 364,	33.3	115
22	The PTEN?PI3K Axis in Cancer. <i>Biomolecules</i> , <b>2019</b> , 9,	5.9	86
21	GILZ-dependent modulation of mTORC1 regulates spermatogonial maintenance. <i>Development</i> (Cambridge), <b>2018</b> , 145,	6.6	12
20	Modeling Cancer-Associated Mutations of PTEN in Mice. <i>Methods in Molecular Biology</i> , <b>2016</b> , 1388, 289-	-3₽¢	1
19	Phosphatase-Independent Functions of the Tumor Suppressor PTEN <b>2016</b> , 247-260		2
18	The Inositol Polyphosphate 5-Phosphatase PIPP Regulates AKT1-Dependent Breast Cancer Growth and Metastasis. <i>Cancer Cell</i> , <b>2015</b> , 28, 155-69	24.3	78
17	The PTEN Tumor Suppressor Forms Homodimers in Solution. <i>Structure</i> , <b>2015</b> , 23, 1952-1957	5.2	23
16	Suppression of T-cell lymphomagenesis in mice requires PTEN phosphatase activity. <i>Blood</i> , <b>2015</b> , 125, 852-5	2.2	12
15	In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes. <i>Cancer Discovery</i> , <b>2015</b> , 5, 740-51	24.4	71

## LIST OF PUBLICATIONS

14	Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus. <i>Nature</i> , <b>2014</b> , 508, 541-5	50.4	232
13	Cancer-associated PTEN mutants act in a dominant-negative manner to suppress PTEN protein function. <i>Cell</i> , <b>2014</b> , 157, 595-610	56.2	190
12	Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. <i>Cancer Discovery</i> , <b>2014</b> , 4, 896-904	24.4	75
11	Role of aberrant PI3K pathway activation in gallbladder tumorigenesis. <i>Oncotarget</i> , <b>2014</b> , 5, 894-900	3.3	41
10	Pills of PTEN? In and out for tumor suppression. <i>Cell Research</i> , <b>2013</b> , 23, 1155-6	24.7	9
9	Functional antagonism between Sall4 and Plzf defines germline progenitors. <i>Cell Stem Cell</i> , <b>2012</b> , 10, 284-98	18	131
8	Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. <i>Cancer Discovery</i> , <b>2012</b> , 2, 1048-63	24.4	335
7	Compound In Vivo Inactivation of Pml and p53 Uncovers a Functional Interaction in Angiosarcoma Suppression. <i>Genes and Cancer</i> , <b>2012</b> , 3, 599-603	2.9	4
6	Pml represses tumour progression through inhibition of mTOR. <i>EMBO Molecular Medicine</i> , <b>2011</b> , 3, 249-	5172	15
5	A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF. <i>Cancer Research</i> , <b>2011</b> , 71, 404-12	10.1	69
4	Regulation of apoptosis by PML and the PML-NBs. <i>Oncogene</i> , <b>2008</b> , 27, 6299-312	9.2	120
3	Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. <i>Journal of Clinical Investigation</i> , <b>2008</b> , 118, 3065-74	15.9	1031
2	Functional cooperation between TrkA and p75(NTR) accelerates neuronal differentiation by increased transcription of GAP-43 and p21(CIP/WAF) genes via ERK1/2 and AP-1 activities. Experimental Cell Research, 2007, 313, 2980-92	4.2	26
1	The PTEN-PI3K Axis in Cancer		3